MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.

PubWeight™: 6.55‹?› | Rank: Top 1%

🔗 View Article (PMID 17297439)

Published in Oncogene on February 12, 2007

Authors

C Welch1, Y Chen, R L Stallings

Author Affiliations

1: Children's Cancer Research Institute and Department of Pediatrics, The University of Texas Health Science Center at San Antonio, MC 7784, TX, USA.

Articles citing this

(truncated to the top 100)

A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25

Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58

MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25

miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24

Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A (2007) 5.50

microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38

OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer (2007) 4.59

MicroRNAs in cancer. Annu Rev Pathol (2009) 4.47

Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3.68

MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66

MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57

p53 and E2f: partners in life and death. Nat Rev Cancer (2009) 3.06

miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89

MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87

MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res (2010) 2.83

The MYCN oncogene is a direct target of miR-34a. Oncogene (2008) 2.80

MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer (2012) 2.78

A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77

MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer (2009) 2.57

Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics (2009) 2.39

The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30

Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 2.28

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25

Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19

A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19

Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest (2014) 2.01

Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet (2011) 2.00

miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J (2011) 1.98

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96

microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle (2010) 1.90

Adult-specific functions of animal microRNAs. Nat Rev Genet (2013) 1.89

Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes (2008) 1.85

p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal (2011) 1.80

Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res (2010) 1.77

MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74

MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer (2010) 1.72

Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch (2011) 1.72

Functional interplay between RNA-binding protein HuR and microRNAs. Curr Protein Pept Sci (2012) 1.71

MicroRNAs, cancer and cancer stem cells. Cancer Lett (2010) 1.65

Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology (2008) 1.63

MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J Immunol (2010) 1.61

Role of miR-34c microRNA in the late steps of spermatogenesis. RNA (2010) 1.60

Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA (2009) 1.60

miR-34: from bench to bedside. Oncotarget (2014) 1.59

Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics (2011) 1.59

Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet (2012) 1.59

MicroRNA-34a Plays a Key Role in Cardiac Repair and Regeneration Following Myocardial Infarction. Circ Res (2015) 1.58

Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A (2011) 1.58

Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One (2009) 1.55

Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog (2009) 1.53

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res (2012) 1.50

MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci U S A (2010) 1.49

MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med (2012) 1.49

Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA (2009) 1.48

Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One (2011) 1.48

MicroRNA expression variability in human cervical tissues. PLoS One (2010) 1.47

Sorting out functions of sirtuins in cancer. Oncogene (2013) 1.47

The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol (2014) 1.47

miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer (2011) 1.46

MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One (2012) 1.45

MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem (2012) 1.43

Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget (2013) 1.43

MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin (2014) 1.40

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer (2011) 1.37

Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood (2007) 1.34

Functional integration of microRNAs into oncogenic and tumor suppressor pathways. Cell Cycle (2008) 1.33

MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis (2014) 1.32

Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29

HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs. J Biol Chem (2011) 1.28

MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis (2012) 1.27

MicroRNAs in ovarian carcinomas. Endocr Relat Cancer (2010) 1.25

MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer (2011) 1.25

Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood (2009) 1.21

Computational analysis of biological functions and pathways collectively targeted by co-expressed microRNAs in cancer. BMC Bioinformatics (2007) 1.21

MicroRNA Regulation of SIRT1. Front Physiol (2012) 1.21

MicroRNA-34a upregulation during seizure-induced neuronal death. Cell Death Dis (2012) 1.20

Over-expression of osa-MIR396c decreases salt and alkali stress tolerance. Planta (2010) 1.20

MicroRNA signature and regulatory functions in the endometrium during normal and disease states. Semin Reprod Med (2008) 1.20

The impact of microRNAs on colorectal cancer. Virchows Arch (2009) 1.20

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat (2011) 1.19

hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer (2010) 1.19

Combinatorial network of primary and secondary microRNA-driven regulatory mechanisms. Nucleic Acids Res (2009) 1.19

miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer (2011) 1.19

MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des (2009) 1.18

miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer (2011) 1.18

miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα. PLoS One (2013) 1.18

Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res (2010) 1.17

Deregulation of microRNAs by HIV-1 Vpr protein leads to the development of neurocognitive disorders. J Biol Chem (2011) 1.17

MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One (2012) 1.17

Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One (2012) 1.16

miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis (2013) 1.16

Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues. PLoS One (2013) 1.14

Apoptosis-associated microRNAs are modulated in mouse, rat and human neural differentiation. BMC Genomics (2010) 1.12

Invited review: decoding the microRNA response to hypoxia. Pflugers Arch (2011) 1.12

Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12

The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One (2014) 1.11

Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene (2011) 1.11

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer (2012) 1.11

Articles by these authors

(truncated to the top 100)

The Ensembl genome database project. Nucleic Acids Res (2002) 40.87

Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80

Ensembl 2009. Nucleic Acids Res (2008) 25.38

Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21

Ensembl 2008. Nucleic Acids Res (2007) 20.67

Ensembl 2007. Nucleic Acids Res (2006) 20.10

Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet (1996) 15.73

Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53

Ensembl 2005. Nucleic Acids Res (2005) 15.13

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35

Ensembl 2002: accommodating comparative genomics. Nucleic Acids Res (2003) 12.26

Ensembl 2004. Nucleic Acids Res (2004) 11.88

Ensembl 2006. Nucleic Acids Res (2006) 11.66

Expression profiling using cDNA microarrays. Nat Genet (1999) 11.58

Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature (1999) 10.97

Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem (1999) 10.14

Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A (2006) 9.26

The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell (2000) 8.95

Data management and analysis for gene expression arrays. Nat Genet (1998) 8.60

Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 8.34

Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Opt (1997) 8.32

Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (2001) 7.66

The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90

Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science (1997) 6.23

Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science (1999) 5.95

Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A (2001) 5.48

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (1997) 5.45

Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J (1998) 5.34

Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20

A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04

Cross-bridge model of muscle contraction. Quantitative analysis. Biophys J (1980) 4.91

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78

Prevention of fat-induced insulin resistance by salicylate. J Clin Invest (2001) 4.74

Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res (1998) 4.68

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature (2000) 4.66

Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet (2001) 4.48

Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology (1998) 4.13

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 3.96

Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem (2000) 3.90

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res (2000) 3.83

A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol (1998) 3.65

Interference of GTP hydrolysis in the mechanism of microtubule assembly: an experimental study. Proc Natl Acad Sci U S A (1984) 3.63

Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science (1999) 3.47

Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature (1996) 3.37

Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev (1996) 3.32

Cooperative effects in models of steady-state transport across membranes. 3. Simulation of potassium ion transport in nerve. Proc Natl Acad Sci U S A (1970) 3.30

Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 3.27

Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc Natl Acad Sci U S A (1998) 3.27

Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science (1998) 3.26

Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae. Mol Biol Cell (1996) 3.23

Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol (2000) 3.08

Scanning two-photon fluctuation correlation spectroscopy: particle counting measurements for detection of molecular aggregation. Biophys J (1996) 3.04

BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01

An SNP map of human chromosome 22. Nature (2000) 2.99

Evidence that mycobacterial PE_PGRS proteins are cell surface constituents that influence interactions with other cells. Infect Immun (2001) 2.98

IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol (1998) 2.97

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1998) 2.92

Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. J Clin Microbiol (1998) 2.91

Rhythmic expression of timeless: a basis for promoting circadian cycles in period gene autoregulation. Science (1995) 2.87

Phase changes at the end of a microtubule with a GTP cap. Proc Natl Acad Sci U S A (1984) 2.87

The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A (1998) 2.85

Structural and magnetic phase diagram of CeFeAsO(1- x)F(x) and its relation to high-temperature superconductivity. Nat Mater (2008) 2.83

Predictors of aspiration pneumonia: how important is dysphagia? Dysphagia (1998) 2.76

Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB. J Biol Chem (1998) 2.75

JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity (1999) 2.74

Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol (1994) 2.70

Cooperative effects in models of steady-state transport across membranes. I. Proc Natl Acad Sci U S A (1970) 2.68

Imprinted X inactivation maintained by a mouse Polycomb group gene. Nat Genet (2001) 2.63

Novel fluorescent protein from Discosoma coral and its mutants possesses a unique far-red fluorescence. FEBS Lett (2000) 2.61

Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin Pharmacol Ther (2009) 2.60

Evidence of bacterial metabolic activity in culture-negative otitis media with effusion. JAMA (1998) 2.58

Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science (1995) 2.55

Resolving heterogeneity on the single molecular level with the photon-counting histogram. Biophys J (2000) 2.55

Termination of Ca2+ release by a local inactivation of ryanodine receptors in cardiac myocytes. Proc Natl Acad Sci U S A (1998) 2.49

A SNP resource for human chromosome 22: extracting dense clusters of SNPs from the genomic sequence. Genome Res (2001) 2.49

NAK is an IkappaB kinase-activating kinase. Nature (2000) 2.44

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet (2004) 2.40

Sequence-specific RNA binding by an SR protein requires RS domain phosphorylation: creation of an SRp40-specific splicing enhancer. Proc Natl Acad Sci U S A (1997) 2.34

Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signalling. Nature (1997) 2.33

Superoxide dismutase enhances tolerance of freezing stress in transgenic alfalfa (Medicago sativa L.). Plant Physiol (1993) 2.32

Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol (2001) 2.31

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab (2010) 2.30

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 2.30

Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses. Oncogene (1999) 2.29

Interactions between endogenous gamma interferon and tumor necrosis factor in host resistance against primary and secondary Listeria monocytogenes infections. Infect Immun (1989) 2.28

27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem (2001) 2.27

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis (2010) 2.24

Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses (2001) 2.23

Use of Monte Carlo calculations in the study of microtubule subunit kinetics. Proc Natl Acad Sci U S A (1983) 2.23

Genetic diversity of Bacillus cereus/B. thuringiensis isolates from natural sources. Curr Microbiol (1998) 2.21

Two-dimensional imaging through diffusing media using 150-fs gated electronic holography techniques. Opt Lett (1991) 2.21

Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A (2001) 2.16

Analysis of gene-specific DNA damage and repair using quantitative polymerase chain reaction. Methods (2000) 2.16

CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem (2000) 2.15

Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem (2000) 2.15

A refined physical map of the long arm of human chromosome 16. Genomics (1991) 2.15

Air pollution and daily mortality in residential areas of Beijing, China. Arch Environ Health (1994) 2.12